? The Gynecologic Oncology Group (GOG) is the premier clinical trial research program investigating new therapeutic approaches in the management of gynecologic malignancies. This multidisciplinary, multimodal Group comprises over 200 participating university and large community hospitals with over 3000 investigator-participants in all specialties of cancer study. An important component of the program is the Committee on Experimental Medicine (CEM) composed of basic and clinical scientists with active studies of cancer translational research. The CEM has oversight over the GOG Tissue Bank through its' Tissue Utilization Subcommittee (TUS). Over the decade of its existence, the GOG Tissue Bank has received and processed tissue from more than 6,100 patients and served over 52,000 specimens to approximately 146 investigators. Over one-half (54%) of all bank registrations are ovarian epithelial malignancies and 52% of these are on a therapeutic protocol. For the general GOG banking protocol (GOG-136), 95% of cases have paired normal tissue (22% with white blood cell pellets), an important adjunct for molecular studies. Nearly 100 institutions submit specimens each year. The number of tissues distributed represents improved access by investigators to the GOG Tissue Bank via NCI web sites and networking of investigators via the Cooperative Human Tissue Network. The GOG Tissue Bank has accounted for 146 scientific papers over the last 10 years, with an increased emphasis on gene expression microarray and proteomics studies within the last two years. The GOG Tissue Bank is poised and flexible to monitor and modify its tissue procurement and distribution technologies to meet changing investigator needs. ? The Specific Aims of this project are: ? 1. Management of specimens from patients enrolled in NCI-sponsored clinical treatment trials to maintain an accurate and effective bank of tumor and normal tissues with associated clinical, epidemiologic and protected health information. ? 2. Promotion of studies by qualified investigators with supervision by the GOG Committee on Experimental Medicine as well as disease-specific committees of the GOG. ? 3. Expansion of innovative technologies facilitating molecular research and increased investigator participation in clinical research trials. ? 4. Maintenance of strict control procedures to ensure high quality capture, processing and distribution of specimens. ? 5. Participation in the development of scientific papers and presentations describing the results of this valuable tissue and data resource. ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Lubensky, Irina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Gynecologic Oncology Group
United States
Zip Code
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
McCourt, Carolyn K; Deng, Wei; Dizon, Don S et al. (2017) A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:101-106
Winder, Abigail D; Maniar, Kruti P; Wei, Jian-Jun et al. (2017) Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer 123:1144-1155
Monk, Bradley J; Facciabene, Andrea; Brady, William E et al. (2017) Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clin Cancer Res 23:1955-1966
Rader, Janet S; Sill, Michael W; Beumer, Jan H et al. (2017) A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:291-297
Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373
McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8
Norquist, Barbara M; Harrell, Maria I; Brady, Mark F et al. (2016) Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2:482-90

Showing the most recent 10 out of 18 publications